NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.395) was uploaded to the NHS England Website on Thursday 7, May 2026.
The following changes have been introduced:
Osimertinib monotherapy (OSI5)
For treating EGFR mutation positive unresectable locally advanced non-small- cell lung cancer after platinum-based chemoradiotherapy where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Pembrolizumab (PEMB35)
Neo-adjuvant followed by adjuvant pembrolizumab for stage III macroscopic resectable melanoma in people 12 years and over where the following criteria have been met
Recommended for routine commissioning (NHS England clinical commissioning policy), added to section B
Belantamab mafodotin in combination with bortezomib and dexamethasone (BELA1)
Belantamab mafodotin in combination with bortezomib and dexamethasone as 2nd line treatment of relapsed or refractory myeloma in adult patients where the following criteria have been met
Date moving into routine commissioning updated; Treatment criterion (#1 and 4) updated; Treatment criterion (#11, 12, 13, 14 and 15) removed
Encorafenib in combination with binimetinib (ENC3)
For the first line treatment of metastatic BRAF V600 mutation positive non-small cell lung cancer where the following criteria have been met
Date moving into routine commissioning updated
Ripretinib (RIP1)
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors where the following criteria have been met
Date moving into routine commissioning updated
Vorasidenib (VOR1)
For treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in patients aged 12 years and over where the following criteria have been met
Date moving into routine commissioning updated
Zanidatamab (ZANI1)
For the treatment of HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatment where the following criteria have been met
Date moving into routine commissioning updated; Treatment criterion (#2, 3 and 5) updated
NA (BOS1)
NA
Removed from section B
NA (CABA1)
NA
Removed from section B
NA (DAS6)
NA
Removed from section B
NA (ERIB1)
NA
Removed from section B
NA (EVE1)
NA
Removed from section B
NA (EVE5)
NA
Removed from section B
NA (EVE6)
NA
Removed from section B
NA (EVE7)
NA
Removed from section B
NA (SOR2)
NA
Removed from section B
NA (SOR3)
NA
Removed from section B
NA (SOR5)
NA
Removed from section B
Belantamab mafodotin with pomalidomide and dexamethasone (BELA2)
Belantamab mafodotin with pomalidomide and dexamethasone as 2nd line treatment of relapsed or refractory myeloma in adult patients who previously received lenalidomide as part of 1st line systemic therapy where the following criteria have been met
Treatment criteria (#1) updated; Treatment criterion (#12, 13, 14, 15 and 16) removed
Nivolumab (NIV25)
Nivolumab plus chemotherapy for neoadjuvant treatment and then continued as adjuvant monotherapy in adults with previously untreated UICC/AJCC 8th edition stage IIA or IIB or IIIA or N2 only IIIB non- small cell lung cancer AND who are candidates for potentially curative surgery where the following criteria have been met
Treatment criteria (#6) updated
Pembrolizumab (PEMB17)
Pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma in patients aged 3 years and older who have NOT been previously treated with stem cell transplantation brentuximab vedotin
Treatment criterion (#1, 11, 13 and 14) updated; Treatment criterion (#2 and 14) removed
Pembrolizumab (PEMB34)
Pembrolizumab for resectable, locally advanced, head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a combined positive score of 1 or more where the following criteria have been met
Treatment criterion (#7 and 8) updated
NA (TEC1)
NA
‘Drug’ column updated; Treatment criterion (#1, 9 and 15) updated; Treatment criterion (#14, 15, 16, 17, 18, 19, 20, 21 and 23) removed
Amivantamab in combination with lazertinib (AMI1)
For the first line treatment of locally advanced or metastatic non-small cell lung cancer in adults whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations where the following criteria have been met
Correction of ‘Date baseline funding started’